Bibliographic Details
| Title: |
1047P AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors. |
| Authors: |
Tran, B.1 (AUTHOR), Millward, M.2 (AUTHOR), Lemech, C.3 (AUTHOR), Frentzas, S.4 (AUTHOR), Day, D.4 (AUTHOR), Latifi, A.5 (AUTHOR), Desai, J.1 (AUTHOR), Wabnitz, P.5 (AUTHOR), Kearney, P.5 (AUTHOR), Galkin, A.5 (AUTHOR) |
| Source: |
Annals of Oncology. 2023 Supplement 2, Vol. 34, pS635-S635. 1p. |
| Database: |
Academic Search Ultimate |
